Coeptis Therapeutics (COEP) said Thursday that it received approval from the Nasdaq Hearings Panel to remain listed on Nasdaq through Jan. 15, 2025.
The company was granted a Nasdaq listing extension after presenting a plan, including a reverse stock split, to address the minimum bid price requirement.
Nasdaq issued a notice of non-compliance with the minimum bid price requirement on Jan. 29, 2024.
Price: 0.2040, Change: +0.03, Percent Change: +16.24
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。